Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.

Christopher Graham, Roy Kao, Qing Cao, Punita Grover, Joseph Norton, Cameron McDonald-Hyman, Joseph Maakaron, Jeremy Allred, Veronika Bachanova, Jeffrey Miller, Daniel Weisdorf, Mark Juckett

Blood (2025) 146 (Supplement 1): 4220.

https://doi.org/10.1182/blood-2025-4220

Published: 2025

Journal Articles

Coronary artery calcification and its effect on cardiac events in patients undergoing allogeneic stem cell transplantation using nonmyeloablative conditioning

Christopher Graham, Roy Kao, Qing Cao, Cameron McDonald-Hyman, Joseph Norton, Punita Grover, Joseph Maakaron, Jeremy Allred, Veronika Bachanova, Jeffrey Miller, Daniel Weisdorf, Mark Juckett

Blood (2025) 146 (Supplement 1): 4219.

https://doi.org/10.1182/blood-2025-4219

Published: 2025

Journal Articles

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Veronika Bachanova, Qing Cao, Marie Hu, Supriya Gupta, Miguel-Angel Perales, Olalekan Oluwole, Richard Maziarz, Joseph McGuirk, Andy Chen, Stephen J. Schuster, Gunjan Shah, Anthony Hunter, Jamie Brower, David Porter, Peter Riedell

Blood (2025) 146 (Supplement 1): 400.

https://doi.org/10.1182/blood-2025-400

Published: 2025

Journal Articles

Risk of relapse and mortality after non-myeloablative allogeneic stem cell transplant for Acute Myeloid Leukemia and myelodysplastic syndrome after fludarabine, cyclophosphamide, and 200 centigray total body irradiation with gvhd prophylaxis using post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil: Impact of maintenance chemotherapy

Christopher Graham, Roy Kao, Qing Cao, Cameron McDonald-Hyman, Joseph Norton, Punita Grover, Joseph Maakaron, Jeremy Allred, Veronika Bachanova, Jeffrey Miller, Daniel Weisdorf, Mark Juckett

Blood (2025) 146 (Supplement 1): 7781.

https://doi.org/10.1182/blood-2025-7781

Published: 2025

Journal Articles

Vedolizumab for steroid-refractory gastrointestinal acute graft-versus-host disease: A real-world VAST study

Le-Qing Cao, Yi Xia, Song Xue, Na Xu, Jian-Ping Zhang, Yang Cao, Yue-Wen Wang, Ze Tian, Jun Kong, Dao-Xing Deng, Xiaohui Zhang, Xiao-Dong Mo

Blood (2025) 146 (Supplement 1): 7772.

https://doi.org/10.1182/blood-2025-7772

Published: 2025

Journal Articles

High neutrophil-to-lymphocyte ratio does not predict MGUS to myeloma progression but is associated with worse survival as a marker of global inflammation

Virginia Hsiao, Colin Tang-Whitmore, Qing Cao, Andinet Teferra, Vidhyalakshmi Ramesh, Aimee Merino, Veronika Bachanova

Blood (2025) 146 (Supplement 1): 5742.

https://doi.org/10.1182/blood-2025-5742

Published: 2025

Journal Articles

Optimizing fludarabine exposure using pharmacokinetic modeling in pediatric patients receiving tisagenlecleucel: A step toward personalized lymphodepletion

Susie Long, Veronika Bachanova, Qing Cao, Christen Ebens, Troy Lund, Margaret MacMillan, Alex Hoover

Blood (2025) 146 (Supplement 1): 2375.

https://doi.org/10.1182/blood-2025-2375

Published: 2025

Journal Articles

Phase I/II clinical trial of bortezomib in combination with CPX-351 for the treatment of newly-diagnosed TP53-mutated Acute Myeloid Leukemia (NCT07008638)

Joseph Norton, Nuttavut Sumransub, Kieth Cordner, Jeremy Allred, Naveen Premnath, Sean Tracy, Craig Eckfeldt, Qing Cao, Mark Juckett, Veronika Bachanova, Zohar Sachs

Blood (2025) 146 (Supplement 1): 3433.

https://doi.org/10.1182/blood-2025-3433

Published: 2025

Journal Articles

Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia

Wenbing Duan, Ying Wu, Wen-Jing Yu, Qi Chen, Zhao Ting, Jing Liu, Le-Qing Cao, Ying-Jun Chang, Xiaosu Zhao, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 1611.

https://doi.org/10.1182/blood-2025-1611

Published: 2025

Journal Articles

Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio Are Associated with Survival in Patients with Monoclonal Gammopathy of Undetermined Significance

Virginia Hsiao, Colin Whitmore, Qing Cao, Aimee Marie Merino, Vidhyalakshmi Ramesh, Andinet Teferra, Veronika Bachanova

Blood (2024) 144 (Supplement 1): 6881.

https://doi.org/10.1182/blood-2024-204376

Published: 2024

Journal Articles

Pre-Treatment Higher Eosinophil Count Is Associated with Improved Survival after Autologous CAR-T Therapy for Hematologic Malignancies

Sana Kagalwalla, Qing Cao, Marie Hu, Joseph E. Maakaron, Daniel O'Leary, Sean Tracy, Veronika Bachanova

Blood (2024) 144 (Supplement 1): 6247.

https://doi.org/10.1182/blood-2024-204198

Published: 2024

Journal Articles

A Phase II Study of Pembrolizumab+ BEAM before Autologous Stem Cell Transplant (ASCT) Followed By Pembrolizumab Maintenance in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma

Sanjal H. Desai, Qing Cao, Marie Hu, Joseph E. Maakaron, Veronika Bachanova

Blood (2024) 144 (Supplement 1): 4434.3.

https://doi.org/10.1182/blood-2024-206187

Published: 2024

Journal Articles

TCRα/β Depleted Mobilized Pbscs without Calcineurin Inhibitors in Patients with Fanconi Anemia

Margaret L. MacMillan, Qing Cao, Martin Felices, Megan Larson, David McKenna, Meera Srikanthan, John E Wagner

Blood (2024) 144 (Supplement 1): 3490.

https://doi.org/10.1182/blood-2024-205404

Published: 2024

Journal Articles

Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Simona Pagliuca, Carmelo Gurnari, Arda Durmaz, Ashwin Kishtagari, Zain Virk, Lukasz P. Gondek, Matthew Guo, Maria Bettinotti, Mark B Juckett, Qing Cao, Suresh Kumar Balasubramanian, Vikram Dhillon, Ben K. Tomlinson, Koen van Besien, Alice Aarnink, Marie Thérèse Rubio, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 927.

https://doi.org/10.1182/blood-2024-210565

Published: 2024

Journal Articles

Vaccination Recommendations and Clinical Characteristics of Children after Allogeneic Hematopoietic Stem Cell Transplantation

Jiaoyang Cai, Wenjuan Chen, Hua Zhang, Jing Chen, YI FEI, Qing Cao

Blood (2023) 142 (Supplement 1): 7022.

https://doi.org/10.1182/blood-2023-181729

Published: 2023

Journal Articles

TP53 -Mutated Acute Myeloid Leukemia Patients Treated with Intensive Therapies Have Superior Outcomes: A Single Institution, Retrospective Study

Nuttavut Sumransub, Gabriel K Steinwand, Yoonkyu Lee, Qing Cao, Jeremy R. Allred, Vidhyalakshmi Ramesh, Chad L Myers, Zohar Sachs

Blood (2023) 142 (Supplement 1): 1526.

https://doi.org/10.1182/blood-2023-177757

Published: 2023

Journal Articles

Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

Shernan G. Holtan, Kelly Walton, Najla H El Jurdi, Joseph E. Maakaron, Mark Juckett, Veronika Bachanova, Thomas Myers, Linda J. Paradiso, Todd DeFor, Qing Cao, Brian Betts

Blood (2023) 142 (Supplement 1): 4925.

https://doi.org/10.1182/blood-2023-181292

Published: 2023

Journal Articles

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide Expedites Donor-Derived Immune Reconstitution in a Pediatric Severe Aplastic Anemia Cohort

Marketa Dimitrov, Svatava Merkle, Qing Cao, Meera Srikanthan, Christen L. Ebens

Blood (2023) 142 (Supplement 1): 7003.

https://doi.org/10.1182/blood-2023-187386

Published: 2023

Journal Articles

Dynamics of Fecal Antibiotic-Resistance Genes after Fecal Microbiota Transplantation in Allogeneic Hematopoietic Cell Transplant Recipients and AML Patients: Results from a Randomized Placebo-Controlled Trial

Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, Hossam Halaweish, Chang Liu, Mohammad H Khan, Andrea Hoeschen, Qing Cao, Xianghua Luo, Amanda Kabage, Sharon Lopez, Shernan G. Holtan, Daniel Weisdorf, Alexander Khoruts, Satoshi Ishii, Christopher M Staley

Blood (2023) 142 (Supplement 1): 4936.

https://doi.org/10.1182/blood-2023-182998

Published: 2023

Journal Articles

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Blood (2022) 140 (Supplement 1): 282–283.

https://doi.org/10.1182/blood-2022-165782

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Coronary artery calcification and its effect on cardiac events in patients undergoing allogeneic stem cell transplantation using nonmyeloablative conditioning

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Vedolizumab for steroid-refractory gastrointestinal acute graft-versus-host disease: A real-world VAST study

High neutrophil-to-lymphocyte ratio does not predict MGUS to myeloma progression but is associated with worse survival as a marker of global inflammation

Optimizing fludarabine exposure using pharmacokinetic modeling in pediatric patients receiving tisagenlecleucel: A step toward personalized lymphodepletion

Phase I/II clinical trial of bortezomib in combination with CPX-351 for the treatment of newly-diagnosed TP53-mutated Acute Myeloid Leukemia (NCT07008638)

Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia

Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio Are Associated with Survival in Patients with Monoclonal Gammopathy of Undetermined Significance

Pre-Treatment Higher Eosinophil Count Is Associated with Improved Survival after Autologous CAR-T Therapy for Hematologic Malignancies

A Phase II Study of Pembrolizumab+ BEAM before Autologous Stem Cell Transplant (ASCT) Followed By Pembrolizumab Maintenance in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma

TCRα/β Depleted Mobilized Pbscs without Calcineurin Inhibitors in Patients with Fanconi Anemia

Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Vaccination Recommendations and Clinical Characteristics of Children after Allogeneic Hematopoietic Stem Cell Transplantation

TP53 -Mutated Acute Myeloid Leukemia Patients Treated with Intensive Therapies Have Superior Outcomes: A Single Institution, Retrospective Study

Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide Expedites Donor-Derived Immune Reconstitution in a Pediatric Severe Aplastic Anemia Cohort

Dynamics of Fecal Antibiotic-Resistance Genes after Fecal Microbiota Transplantation in Allogeneic Hematopoietic Cell Transplant Recipients and AML Patients: Results from a Randomized Placebo-Controlled Trial

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only